Carboplatin and etoposide chemotherapy in extrapulmonary poorly differentiated neuroendocrine carcinomas

被引：0
|
作者：
Galdy, S. [1 ]
Aurilio, G. [1 ]
Radice, D. [1 ]
Spada, F. [1 ]
Cella, C. A. [1 ]
Frezza, A. M. [1 ]
Nole, F. [1 ]
Fazio, N. [1 ]
机构：
[1] Ist Europeo Oncol, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
R20
引用
收藏
页码：138 / 138
页数：1
相关论文
共 50 条
  • [41] Therapeutic management of poorly differentiated neuroendocrine lung tumors and neuroendocrine carcinomas of the digestive system
    Pellat, Anna
    Wislez, Marie
    Svrcek, Magali
    Hammel, Pascal
    Afchain, Pauline
    Andre, Thierry
    BULLETIN DU CANCER, 2016, 103 (10) : 880 - 895
  • [42] Current concepts in the diagnosis and management of poorly differentiated gastrointestinal neuroendocrine carcinomas
    Koumarianou, Anna
    Chatzellis, Eleftherios
    Boutzios, Georgios
    Tsavaris, Nikolaos
    Kaltsas, Gregory
    ENDOKRYNOLOGIA POLSKA, 2013, 64 : 8 - 21
  • [43] Poorly Differentiated Neuroendocrine Carcinomas of the Pancreas A Clinicopathologic Analysis of 44 Cases
    Basturk, Olca
    Tang, Laura
    Hruban, Ralph H.
    Adsay, Volkan
    Yang, Zhaohai
    Krasinskas, Alyssa M.
    Vakiani, Efsevia
    La Rosa, Stefano
    Jang, Kee-Taek
    Frankel, Wendy L.
    Liu, Xiuli
    Zhang, Lizhi
    Giordano, Thomas J.
    Bellizzi, Andrew M.
    Chen, Jey-Hsin
    Shi, Chanjuan
    Allen, Peter
    Reidy, Diane L.
    Wolfgang, Christopher L.
    Saka, Burcu
    Rezaee, Neda
    Deshpande, Vikram
    Klimstra, David S.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2014, 38 (04) : 437 - 447
  • [44] Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: A Minnie Pearl Cancer Research Network Study
    Hainsworth, John D.
    Spigel, David R.
    Litchy, Sharlene
    Greco, F. Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (22) : 3548 - 3554
  • [45] Cisplatin plus etoposide as first-line chemotherapy for poorly-differentiated neuroendocrine carcinoma of the hepatobiliary and pancreatic region
    Iwasa, S.
    Morizane, C.
    Okusaka, T.
    Ueno, H.
    Ikeda, M.
    Kondo, S.
    Kojima, Y.
    Hagihara, A.
    Hiraoka, N.
    EJC SUPPLEMENTS, 2009, 7 (02): : 396 - 396
  • [46] Current concepts in the diagnosis and management of poorly differentiated gastrointestinal neuroendocrine carcinomas
    Koumarianou, Anna
    Chatzellis, Eleftherios
    Boutzios, Georgios
    Tsavaris, Nikolaos
    Kaltsas, Gregory
    ENDOKRYNOLOGIA POLSKA, 2013, 64 (01) : 60 - 72
  • [47] Prognosis for Poorly Differentiated, High-Grade Rectal Neuroendocrine Carcinomas
    Derek J. Erstad
    Arvind Dasari
    Melissa W. Taggart
    Harmeet Kaur
    Tsuyoshi Konishi
    Brian K. Bednarski
    George J. Chang
    Annals of Surgical Oncology, 2022, 29 : 2539 - 2548
  • [48] Efficacy of 2nd-line Chemotherapy in Patients With Poorly Differentiated, High Grade Extrapulmonary Neuroendocrine Carcinoma (PD NEC)
    McGarrah, Patrick
    Leventakos, Konstantinos
    Westin, Gustavo
    Finnes, Heidi
    Molina, Julian
    Hobday, Timothy
    Halfdanarson, Thorvardur
    PANCREAS, 2019, 48 (03) : 446 - 446
  • [49] Efficacy of 2nd-line chemotherapy in patients with poorly differentiated, high grade extrapulmonary neuroendocrine carcinoma (PD NEC).
    McGarrah, Patrick Walsh
    Leventakos, Konstantinos
    Hobday, Timothy J.
    Molina, Julian R.
    Finnes, Heidi Diann
    Halfdanarson, Thorvardur Ragnar
    Westin, Gustavo Figueiredo Marcondes
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [50] Activity and Safety of Avelumab in High-Grade Neuroendocrine Tumors and Poorly Differentiated Neuroendocrine Carcinomas Progressive after Chemotherapy (AveNEC Trial)
    Fottner, Christian
    Apostolidis, Leonidas
    Krug, Sebastian
    Rinke, Anja
    Gruen, Barbara
    Michl, Patrick
    Gress, Thomas M.
    Wagner, Daniel-Christoph
    Roth, Wilfried
    Mettler, Esther
    Topsch, Jana
    Ruckes, Christian
    Galle, Peter R.
    Weber, Matthias M.
    CLINICAL CANCER RESEARCH, 2025, 31 (05) : 860 - 867
12345